Le Lézard
Classified in: Science and technology
Subjects: CCA, FVT

Hortonworks to Announce Fourth Quarter and Fiscal Year 2017 Results on February 8, 2018


SANTA CLARA, Calif., Jan. 23, 2018 /PRNewswire/ -- Hortonworks, Inc. (NASDAQ: HDP) will report results for its fourth quarter and fiscal year ended December 31, 2017 on February 8, 2018. The results will be included in a press release with accompanying financial information that will be released after market close and posted on the Hortonworks Investor Relations website.

Hortonworks logo. (PRNewsFoto/Hortonworks)

Hortonworks' executive management team will host a conference call on February 8, 2018 beginning at 1:30 p.m. PT (4:30 p.m. ET) to discuss financial results and business highlights. Prepared remarks will also be published on the Hortonworks Investor Relations website after market close. Interested parties may access the call by dialing (877) 930-7786 in the U.S. or (253) 336-7423 from international locations. In addition, a live audio webcast of the conference call will be available on Hortonworks' Investor Relations website at http://investors.hortonworks.com.

Shortly after the conclusion of the conference call, a replay of the audio webcast will be available on Hortonworks' Investor Relations website for approximately seven days.

About Hortonworks

Hortonworks is a leading provider of enterprise-grade, global data management platforms, services and solutions that deliver actionable intelligence from any type of data for over half of the Fortune 100.  Hortonworks is committed to driving innovation in open source communities, providing unique value to enterprise customers. Along with its partners, Hortonworks provides technology, expertise and support so that enterprise customers can adopt a modern data architecture. For more information, visit www.hortonworks.com.

Hortonworks is a registered trademark or trademark of Hortonworks, Inc. and its subsidiaries in the United States and other jurisdictions. All other trademarks are the property of their respective owners.

For additional information, contact:
Reuben Gallegos
VP, Investor Relations & Corporate Development
[email protected]

 

SOURCE Hortonworks, Inc.


These press releases may also interest you

at 07:05
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
MindMed to Present at Upcoming May Medical Conferences
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Firms in France Seek to Squeeze More Value From Salesforce
Enterprises in France, seeking better returns on investment, are turning to service providers that can manage their Salesforce platforms more efficiently, according to a new research report published today by Information Services Group (ISG) , a...

at 07:05
Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...

More news about Science and technology...


News published on and distributed by: